A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First-in-Human Study Evaluating Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered BMS-986521 in Healthy Adult Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: First line of the email MUST contain the NCT# and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- Recruiting
- CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
-
Contact:
- Peter Winkle, Site 0001
- Phone Number: 949-295-7809
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be healthy males and females (assigned at birth) who are not of childbearing potential, with no clinically significant abnormalities in medical history, physical exam, ECG, or lab tests.
- Participants must have a body mass index (BMI) between 18 and 32 kg/m² (inclusive) and body weight of at least 50 kg.
- For Part B/Cohort 11 only: participants with stable cardiovascular conditions may be included if deemed suitable by the investigator.
Exclusion Criteria:
- Participants must not have any significant medical condition or history (renal, hepatic, hematologic, GI, endocrine, pulmonary, neurologic, or immunologic) that may affect drug absorption, distribution, metabolism, or excretion (ADME), or pose a risk to the participant.
- Participants must not have a history of rhabdomyolysis, cancer (except certain cured skin or cervical cancers), hematologic malignancy, or myelodysplastic syndrome.
- Participants must not have recent or current significant GI disease, major surgery, or medical interventions affecting ADME (except appendectomy or cholecystectomy).
- Participants must not have had a blood transfusion within 4 weeks or have an inability to tolerate oral medication or venous access.
- Other protocol defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A Cohort 1
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part A Cohort 2
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part A Cohort 3
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part A Cohort 4
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part A Cohort 5
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part C
|
Specified dose on specified days.
|
|
Experimental: Part A Cohort 6
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part B Cohort 7
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part B Cohort 8
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part B Cohort 9
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part B Cohort 10
|
Specified dose on specified days
Specified dose on specified days.
|
|
Experimental: Part B Cohort 11
|
Specified dose on specified days
Specified dose on specified days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment-emergent adverse events (AEs)
Time Frame: Up to approximately Day 40
|
Up to approximately Day 40
|
|
Number of participants with treatment-emergent serious adverse events (SAEs)
Time Frame: Up to approximately Day 40
|
Up to approximately Day 40
|
|
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Concentration (Cmax) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Time to Cmax (Tmax) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Area Under the Concentration-Time Curve from Time Zero to the Last Measured Time Point (AUC(0-T)) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Area Under the Concentration-Time Curve from Time Zero to 24 Hours (AUC(0-24)) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC(INF)) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Concentration Over a Dosing Interval (tau) (AUC(TAU)) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Elimination Half-Life (T-HALF) of BMS-986521 in Plasma
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Apparent Clearance of BMS-986521 from Plasma after Dosing (CLT/F)
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Apparent Volume of Distribution in Plasma after Dosing (Vz/F) of BMS-986521
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Accumulation Index Based on Maximum Concentration (Cmax) in Plasma after Multiple Dosing (AI_Cmax) of BMS-986521
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Accumulation Index Based on Area Under the Curve (AUC) in Plasma After Multiple Dosing (AI_AUC) of BMS-986521
Time Frame: Up to approximately Day 14
|
Up to approximately Day 14
|
|
|
Geometric Mean Cmax BMS-986521 under fed and fasted conditions
Time Frame: Up to approximately Day 11
|
Cohort 3
|
Up to approximately Day 11
|
|
Geometric Mean AUC(0-T) BMS-986521 under fed and fasted conditions
Time Frame: Up to approximately Day 11
|
Cohort 3
|
Up to approximately Day 11
|
|
Geometric Mean AUC(INF) BMS-986521 under fed and fasted conditions
Time Frame: Up to approximately Day 11
|
Cohort 3
|
Up to approximately Day 11
|
|
Geometric mean ratios of Cmax for BMS-986521 oral tablet vs solution
Time Frame: Up to approximately Day 11
|
Part C
|
Up to approximately Day 11
|
|
Geometric mean ratios of AUC(0-T) for BMS-986521 oral tablet vs solution
Time Frame: Up to approximately Day 11
|
Part C
|
Up to approximately Day 11
|
|
Geometric mean ratios of AUC(INF) for BMS-986521 oral tablet vs solution
Time Frame: Up to approximately Day 11
|
Part C
|
Up to approximately Day 11
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- CN014-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:
https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.